Document Detail

Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
MedLine Citation:
PMID:  20703506     Owner:  NLM     Status:  In-Process    
In a non-comparative study, caspofungin was effective salvage therapy for approximately half of the patients refractory to or intolerant of standard antifungal agents for invasive aspergillosis. To establish a frame of reference for these results, we compared the response to caspofungin with responses to other antifungal agents in a historical cohort of similar patients. The efficacy could be evaluated in 83 patients who received caspofungin 50 mg daily after a 70-mg loading dose. The historical control group, identified through a retrospective review of medical records, included 214 evaluable patients possibly refractory to or intolerant of ≥1 week of standard antifungal therapy. All patients had documented invasive aspergillosis. Favorable response was defined as a complete or partial response to therapy. Underlying diseases, baseline neutropenia, corticosteroid use, and sites of infection were similar in both studies. Most patients had received amphotericin B formulations and/or itraconazole, and were refractory to standard therapy. Favorable response rates were 45% with caspofungin and 16% with standard therapy. The unadjusted odds ratio for a favorable response (caspofungin/standard therapy) was 4.1 (95% confidence interval: 2.2, 7.5). After adjusting for potential imbalances in the frequency of disseminated infection, neutropenia, steroid use, and bone marrow transplantation between groups, the odds ratio remained at 4.1 (2.1, 7.9). Although only tentative conclusions about relative efficacy can be drawn from retrospective comparisons, caspofungin appeared to be at least as efficacious as an amphotericin B formulation and/or itraconazole for the treatment of invasive aspergillosis in patients refractory to or intolerant of their initial antifungal therapy.
J W Hiemenz; I I Raad; J A Maertens; R Y Hachem; A J Saah; C A Sable; J A Chodakewitz; M E Severino; P Saddier; R S Berman; D M Ryan; M J Dinubile; T F Patterson; D W Denning; T J Walsh
Related Documents :
19947856 - Linezolid in the treatment of multidrug-resistant tuberculosis.
2665766 - Tuberculosis: a six-month cure.
10949326 - Progress and problems in achieving the united states national target for completion of ...
17985576 - Mirazid (commiphora molmol) in treatment of human heterophyiasis.
15551656 - Effect of adventitial dissection in brachiobasilic arteriovenous fistulae opened in chi...
9783616 - Kapandji pinning or closed reduction for extra-articular distal radius fractures.
Publication Detail:
Type:  Journal Article     Date:  2010-08-12
Journal Detail:
Title:  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology     Volume:  29     ISSN:  1435-4373     ISO Abbreviation:  Eur. J. Clin. Microbiol. Infect. Dis.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8804297     Medline TA:  Eur J Clin Microbiol Infect Dis     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1387-94     Citation Subset:  IM    
Division of Hematology/Oncology, University of Florida College of Medicine, P.O. Box 100278, Gainesville, FL, 32610-0278, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The first clinical case in Japan of destination therapy using the Jarvik 2000 left ventricular assis...
Next Document:  Elevated serum levels of bromine do not always indicate pseudohyperchloremia.